LUBBOCK, TX, USA, October 4, 2022 /EINPresswire.com/ — NemaLife Inc., a techbio company specializing in high-throughput in vivo screening, is delighted to announce that it has joined the International Probiotic Association (APIs). This global non-profit organization brings together various stakeholders in the probiotics industry to promote the safe and effective use of probiotics for human health and well-being.
A major bottleneck for the development of new probiotics is the lack of rapid preclinical testing solutions that can assess the health benefits of new bacterial strains. NemaLife has developed an automated and scalable in vivo test platform that combines the microscopic C. elegans worm, microfluidics and artificial intelligence. This industry-validated platform addresses the limitations of in vitro models (e.g., TIM-2) and provides an alternative to expensive, time-consuming, and energy-intensive rodent testing. NemaLife’s 3R-Ready Platform Also Aligns With US Senate Approval FDA Modernization Act 2.0 which obliges to reduce the tests on the mammals.
Marton Toth, Ph.D., Chief Commercial Officer of NemaLife, said, “We are delighted to join the IPA, the premier organization connecting industry, academia and regulators in the probiotics sector. NemaLife’s AI-assisted platform can establish the health benefits of new strains in different areas, such as obesity, gut health, muscle health, healthy aging, and cognitive health, by a few weeks compared to mammalian studies. This compelling value proposition will radically transform probiotic development. Our IPA membership is an ideal channel to engage with industry stakeholders and introduce a new industry standard for preclinical testing.
“IPA is recognized as the unified global voice for probiotics” around the world, and we are thrilled to work with and welcome NemaLife to our community. The diversity of microbial strains discovered poses new challenges throughout the value chain of pro/postbiotic product development. NemaLife’s new technology can fill critical gaps in this value chain by offering rapid in vivo data to guide R&D decision-making. Our IPA members are always looking for new solutions, and NemaLife’s cruelty-free approach has the potential to become the new industry standard for preclinical testing,” said George Paraskevakos, Executive Director, IPA.
NemaLife’s innovative platform will be unveiled on November 3 at the IPA Probiotics Research Center during the Supply Side West show in Las Vegas. Dr. Dhaval Patel, Director of Research and Innovation at NemaLife, will present this platform and how it can be used to help companies accelerate the discovery of beneficial bacteria to develop safe and effective probiotics.
NemaLife is a techbio platform company developing AI and microfluidics-based solutions for various industries to reduce the costs and carbon footprint associated with screening. Its low-cost, patented whole-organism tests help reduce risk and accelerate product development by providing actionable data that reduces the use of mammals in preclinical testing. NemaLife’s technology is designed with scalability and versatility in mind, helping innovative companies and academic labs accelerate their R&D and scientific discovery to improve the quality of human life on a healthy planet.
For more information, visit www.nemalifeinc.com
Investor and media contacts
For more information and inquiries, please contact: email@example.com and firstname.lastname@example.org.